, petit e, park yw, du tezenas montcel s, joers jm, ation of serum neurofilament light and disease severity in patients dubois jm, et al. sensitivity of advanced magnetic resonance with spinocerebellar ataxia type 3. neurology. 2020 ; 95 : e2977 â€“ 87. imaging to progression over six months in early spinocerebellar 32. li q - f, dong y, yang l, xie j - j, ma y, du y - c, et al. neurofila - ataxia. mov disord. 2024. https : / / doi. org / 1 0. 1 0 0 2 / m d s. 2 9 9 3 4. ment light chain is a promising serum biomarker in spinocerebel - 47. nigri a, sarro l, mongelli a, pinardi c, porcu l, castaldo a, lar ataxia type 3. mol neurodegener. 2019 ; 14 : 39. https : / / doi. org / et al. progression of cerebellar atrophy in spinocerebellar ataxia 1 0. 1 1 8 6 / s 1 3 0 2 4 - 0 1 9 - 0 3 3 8 - 0. type 2 gene carriers : a longitudinal mri study in preclinical and 33. coarelli g, dubec - fleury c, petit e, sayah s, fischer c, nassisi early disease stages. front neurol. 2020 ; 11 : 616419. https : / / doi. or m, et al. longitudinal changes of clinical, imaging, and fluid bio - g / 1 0. 3 3 8 9 / f n e u r. 2 0 2 0. 6 1 6 4 1 9. markers in preataxic and early ataxic spinocerebellar ataxia type 48. chandrasekaran j, petit e, park yw, du montcel st, joers jm, 2 and 7 carriers. neurology. 2024 ; 103 : e209749. https : / / doi. org / 1 deelchand dk, et al. clinically meaningful magnetic resonance 0. 1 2 1 2 / w n l. 0 0 0 0 0 0 0 0 0 0 2 0 9 7 4 9. endpoints sensitive to preata